<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>STTR Phase II:  A Novel Abdominal Stimulator to Assist with Ventilator Weaning in Patients</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>09/15/2016</AwardEffectiveDate>
<AwardExpirationDate>09/30/2021</AwardExpirationDate>
<AwardTotalIntnAmount>749408.00</AwardTotalIntnAmount>
<AwardAmount>1407653</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Alastair Monk</SignBlockName>
<PO_EMAI>amonk@nsf.gov</PO_EMAI>
<PO_PHON>7032924392</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project, in which a non-invasive respiratory muscle stimulation device and approach to weaning patients from mechanical ventilation will be developed, is a reduction in public health care expenditure and a reduction in morbidity for the half a million patients who have difficulty weaning from mechanical ventilation each year in the US. These patients suffer from an array of clinical complications (for example, pneumonia) and cost the US health care system $16 billion annually, a great deal of which is borne by Medicare and Medicaid. In addition, the current reimbursement landscape economically incentivizes hospitals to wean patients at the earliest possible time. The proposed innovation has the potential to positively benefit society by providing a solution to this serious healthcare problem. In addition, it promises to improve our scientific understanding of respiratory muscle physiology and mechanics in difficult to wean patients. It will also improve our technical understanding of non-invasive respiratory sensors and biofeedback algorithms for the purposes of electrical muscle stimulation. Finally, as demonstrated by the number and cost of difficult to wean patients, as well as current healthcare reimbursement policies, the proposed innovation has potential to results in a considerable commercial impact.  &lt;br/&gt; &lt;br/&gt;The proposed project will develop a non-invasive electrical stimulator that automatically applies stimulation to the respiratory muscles in synchrony with a patient?s voluntary breathing pattern. This approach is expected to address the imbalance between respiratory muscle strength and respiratory muscle load - a major factor responsible for weaning difficulty - by assisting ventilation during weaning sessions and strengthening the breathing muscles that have become weakened as a result of mechanical ventilation. In Phase 1 a functional prototype was developed; clinical feasibility of the approach was also demonstrated.  The Phase II proposal focuses on refining the stimulation algorithm to maximize its clinical effectiveness and on developing a novel stimulation electrode system so that the device can be quickly applied to patients. In addition, methods will be developed to interface the technology with a mechanical ventilator to expand its clinical application. Finally, a complete works-like, looks-like prototype will be developed that is designed to international standards and is safe for clinical testing. The work completed in this Phase of the project will enable a controlled clinical trial of the proposed approach and ultimately allow the device to gain FDA regulatory clearance.</AbstractNarration>
<MinAmdLetterDate>09/07/2016</MinAmdLetterDate>
<MaxAmdLetterDate>02/18/2021</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>1632402</AwardID>
<Investigator>
<FirstName>Angus</FirstName>
<LastName>Mclachlan</LastName>
<PI_MID_INIT>J</PI_MID_INIT>
<PI_SUFX_NAME>Mr.</PI_SUFX_NAME>
<PI_FULL_NAME>Angus J Mclachlan</PI_FULL_NAME>
<EmailAddress>angus@liberatemedical.com</EmailAddress>
<PI_PHON>5022414114</PI_PHON>
<NSF_ID>000646042</NSF_ID>
<StartDate>09/07/2016</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Franco</FirstName>
<LastName>Laghi</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Franco Laghi</PI_FULL_NAME>
<EmailAddress>flaghi@lumc.edu</EmailAddress>
<PI_PHON>5022414114</PI_PHON>
<NSF_ID>000661484</NSF_ID>
<StartDate>09/07/2016</StartDate>
<EndDate/>
<RoleCode>Co-Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>Liberate Medical LLC</Name>
<CityName>Crestwood</CityName>
<ZipCode>400146773</ZipCode>
<PhoneNumber>5024033964</PhoneNumber>
<StreetAddress>6400 Westwind Way</StreetAddress>
<StreetAddress2><![CDATA[Suite A]]></StreetAddress2>
<CountryName>United States</CountryName>
<StateName>Kentucky</StateName>
<StateCode>KY</StateCode>
<CONGRESSDISTRICT>04</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>KY04</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>078763522</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>LIBERATE MEDICAL LLC</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[Edward Hines, Jr. VA Hospital]]></Name>
<CityName>HInes</CityName>
<StateCode>IL</StateCode>
<ZipCode>601413030</ZipCode>
<StreetAddress><![CDATA[5000 South 5th Avenue]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Illinois</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>07</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>IL07</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>1591</Code>
<Text>STTR Phase II</Text>
</ProgramElement>
<ProgramElement>
<Code>5373</Code>
<Text>SBIR Phase II</Text>
</ProgramElement>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<ProgramReference>
<Code>124E</Code>
<Text>CENTERS: BIOENG &amp; HEALTH CARE</Text>
</ProgramReference>
<ProgramReference>
<Code>1591</Code>
<Text>STTR PHASE II</Text>
</ProgramReference>
<ProgramReference>
<Code>165E</Code>
<Text>SBIR Phase IIB</Text>
</ProgramReference>
<ProgramReference>
<Code>5345</Code>
<Text>BIOMEDICAL ENGINEERING</Text>
</ProgramReference>
<ProgramReference>
<Code>8038</Code>
<Text>Biotechnology</Text>
</ProgramReference>
<ProgramReference>
<Code>8042</Code>
<Text>Health and Safety</Text>
</ProgramReference>
<ProgramReference>
<Code>8240</Code>
<Text>SBIR/STTR CAP</Text>
</ProgramReference>
<ProgramReference>
<Code>9150</Code>
<Text>EXP PROG TO STIM COMP RES</Text>
</ProgramReference>
<Appropriation>
<Code>0116</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<Appropriation>
<Code>0118</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<Appropriation>
<Code>0120</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2016~749408</FUND_OBLG>
<FUND_OBLG>2018~508366</FUND_OBLG>
<FUND_OBLG>2020~149879</FUND_OBLG>
</Award>
</rootTag>
